These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25678082)
1. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Mahal K; Biersack B; Caysa H; Schobert R; Mueller T Invest New Drugs; 2015 Jun; 33(3):541-54. PubMed ID: 25678082 [TBL] [Abstract][Full Text] [Related]
2. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355 [TBL] [Abstract][Full Text] [Related]
3. Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. Mahal K; Ahmad A; Sethi S; Resch M; Ficner R; Sarkar FH; Schobert R; Biersack B Cell Oncol (Dordr); 2015 Dec; 38(6):463-78. PubMed ID: 26358135 [TBL] [Abstract][Full Text] [Related]
4. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential. Muenzner JK; Biersack B; Kalie H; Andronache IC; Kaps L; Schuppan D; Sasse F; Schobert R ChemMedChem; 2014 Jun; 9(6):1195-204. PubMed ID: 24648184 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents. Conesa-Milián L; Falomir E; Murga J; Carda M; Meyen E; Liekens S; Alberto Marco J Eur J Med Chem; 2018 Mar; 147():183-193. PubMed ID: 29432949 [TBL] [Abstract][Full Text] [Related]
6. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models. Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410). Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336 [TBL] [Abstract][Full Text] [Related]
8. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416 [TBL] [Abstract][Full Text] [Related]
9. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Mahal K; Kahlen P; Biersack B; Schobert R Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles. Biersack B; Muthukumar Y; Schobert R; Sasse F Bioorg Med Chem Lett; 2011 Nov; 21(21):6270-3. PubMed ID: 21963303 [TBL] [Abstract][Full Text] [Related]
11. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678 [TBL] [Abstract][Full Text] [Related]
13. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236 [TBL] [Abstract][Full Text] [Related]
15. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects. Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033 [TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131 [TBL] [Abstract][Full Text] [Related]
17. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bellina F; Cauteruccio S; Monti S; Rossi R Bioorg Med Chem Lett; 2006 Nov; 16(22):5757-62. PubMed ID: 16950621 [TBL] [Abstract][Full Text] [Related]
18. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization. Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052 [TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. Mahal K; Biersack B; Schruefer S; Resch M; Ficner R; Schobert R; Mueller T Eur J Med Chem; 2016 Aug; 118():9-20. PubMed ID: 27116710 [TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]